Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2018 Oct 8;9:2326. doi: 10.3389/fimmu.2018.02326

Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset

Stephan Kloess 1,*, Alessa Ede Valverde da Silva 1, Olaf Oberschmidt 1, Tanja Gardlowski 1, Nadine Matthies 1, Maulik Vyas 2, Lubomir Arseniev 1, Michael Heuser 3, Elke Pogge von Strandmann 4, Ulrike Köhl 1
PMCID: PMC6187021  PMID: 30344526

In the original article, we neglected to include the following funding information:

This study was supported by a grant from the Deutsche Jose Carreras Leukämie-Stiftung to ES (DJCLS R 1408).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES